Literature DB >> 30971464

GeneXpert MTB/RIF Is Superior to BBD Max MDR-TB for Diagnosis of Tuberculosis (TB) in a Country with Low Incidence of Multidrug-Resistant TB (MDR-TB).

E M Mokaddas1,2, S Ahmad3, H S Eldeen2.   

Abstract

Entities:  

Keywords:  BBD Max MDR-TB; GeneXpert MTB/RIF Ultra; Mycobacterium tuberculosiszzm321990; performance comparison; rapid diagnosis

Mesh：

Substances：

Year:  2019        PMID： 30971464      PMCID： PMC6535618          DOI： 10.1128/JCM.00537-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  4 in total

Review 1.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

Review 2.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

3.  Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005.

Authors:  E Mokaddas; S Ahmad; I Samir
Journal:  Int J Tuberc Lung Dis       Date:  2008-03       Impact factor: 2.373

4.  Discordance across Phenotypic and Molecular Methods for Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Low TB Incidence Country.

Authors:  Suhail Ahmad; Eiman Mokaddas; Noura Al-Mutairi; Hanaa S Eldeen; Shirin Mohammadi
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240
  4 in total
  6 in total

1.  Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays.

Authors:  Patrick Murray; Charles Cooper; Courtney Maus
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

2.  Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays".

Authors:  Eiman M Mokaddas; Suhail Ahmad; Hanaa S Eldeen
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

Review 3.  Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.

Authors:  Samantha Pillay; Karen R Steingart; Geraint R Davies; Marty Chaplin; Margaretha De Vos; Samuel G Schumacher; Rob Warren; Grant Theron
Journal:  Cochrane Database Syst Rev       Date:  2022-05-18

Review 4.  The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.

Authors:  Daniel H F Rubin; Jonathan D C Ross; Yonatan H Grad
Journal:  Transl Res       Date:  2020-02-29       Impact factor: 7.012

5.  Performance Comparison of GeneXpert MTB/RIF and ProbeTec ET Tests for Rapid Molecular Diagnosis of Extrapulmonary Tuberculosis in a Low TB/MDR-TB Incidence Country.

Authors:  Eiman Mokaddas; Suhail Ahmad; Hanaa Eldeen
Journal:  Med Princ Pract       Date:  2021-02-16       Impact factor: 1.927

6.  A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB/Rif Ultra and FluoroType MTB.

Authors:  Markus Beutler; Sara Plesnik; Marina Mihalic; Laura Olbrich; Norbert Heinrich; Samuel Schumacher; Michael Lindner; Ina Koch; Wolfgang Grasse; Christoph Metzger-Boddien; Sabine Hofmann-Thiel; Harald Hoffmann
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.